Back to VRTX Stock Lookup

Vertex Pharma (VRTX) – Company Press Releases

Sep 8, 2014 09:00 AM Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014
Sep 2, 2014 04:01 PM Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10
Jul 31, 2014 04:18 PM Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
Jul 29, 2014 04:01 PM Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs
Jul 14, 2014 04:01 PM Vertex to Announce Second Quarter 2014 Financial Results on July 29
Jul 10, 2014 08:00 AM Vertex Announces Retirement of Peter Mueller, Ph.D.
Jun 30, 2014 04:05 PM Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation
Jun 27, 2014 07:14 AM Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
Jun 24, 2014 07:00 AM Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have

Back to VRTX Stock Lookup